Diagnostics

The new over-the-counter molecular test could deliver results in 30 minutes, aiming to revolutionize STI diagnostics and tap into a $1.5B market.

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

Prenetics slashed future dilution risk by exchanging 4.7M warrants, a move analysts see as crucial for fueling the rapid growth of its IM8 wellness brand.

A major new partnership is funding research to develop vital diagnostic tests for FTD, aiming to end years-long diagnostic delays for families.

A major study reveals dropping MMR vaccination rates and a surge in measles, but identifies a key window for pediatricians to prevent missed immunizations.

Lantheus sells its legacy SPECT business to fusion-tech firm SHINE, sharpening its focus on high-growth PET diagnostics and next-gen cancer therapies.

With a blockbuster 2025 in the books, Boston Scientific's leadership faces intense scrutiny at upcoming investor events to prove its growth is sustainable.

With patent cliffs looming and big bets on M&A, all eyes are on BMS to prove its growth strategy and high-stakes pipeline can deliver in 2026.

At CES 2026, PETKIT unveiled an AI ecosystem that turns feeders and litter boxes into health monitors, promising to catch illnesses in pets early.

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

After a year of major acquisitions and AI-driven innovation, all eyes are on Labcorp's strategic vision for 2026 at the J.P. Morgan Healthcare Conference.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Fresh off a successful IPO, Ceribell is set to showcase its revolutionary AI-powered EEG system, a device already changing outcomes in ICUs nationwide.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

Veracyte prepares for the J.P. Morgan conference, where it will showcase its AI and genomic strategy amid strong financials and a competitive market.

The med-tech firm has submitted its AI-assisted capsule endoscopy module to the FDA, promising faster, more accurate, and accessible GI disease detection.

With soaring revenue and a landmark FDA approval for its Shield cancer test, Guardant Health's upcoming JPM presentation is poised to define its future.

A private tender offer values diagnostics firm PathoCare at $1.75B. Can its AI-powered, non-invasive technology justify the price and transform medicine?

A new partnership aims to boost low colorectal cancer screening rates by combining trusted patient education with the promise of simpler blood-based tests.

Sofie Biosciences begins late-stage trials for a novel PET scan targeting aggressive gastrointestinal cancers, a breakthrough that could redefine detection.